Treatment of migraine with monoclonal antibodies

References

• Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021 Dec 19;396(10267):2006–2017.
   PubMed Web of Science ®Google Scholar
• Foster SA, Hoyt M, Ye W, et al. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Curr Med Res Opin. 2021 Nov 11:1–25. DOI: 10.1080/03007995.2021.2003127.
   Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.
   PubMed Web of Science ®Google Scholar
• Negro A, Spuntarelli V, Sciattella P, et al. Rapid referral for headache management from emergency department to headache centre: four years data. J Headache Pain. 2020;21(1):25.
   PubMed Web of Science ®Google Scholar
• Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–1876.
   PubMed Web of Science ®Google Scholar
• de Boer I, van den Maagdenberg AMJM, Terwindt GM. Advance in genetics of migraine. Curr Opin Neurol. 2019;32(3):413–421.
   PubMed Web of Science ®Google Scholar
• Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619–6629.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (®). The International Classification of Headache Disorders 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
   PubMed Web of Science ®Google Scholar
• Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia. 2019;39(3):374–389.
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–425.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30(3):272–280.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al., Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366–373.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994;14(5):320–327.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Osorio X, Sobrino T, Brea D, et al. Endothelial progenitor cells: a new key for endothelial dysfunction in migraine. Neurology. 2012;79(5):474–479.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015;35(4):310–316.
   PubMed Web of Science ®Google Scholar
• Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Network Open. 2021;4(10):e2128544.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(2):47–55.
   PubMedGoogle Scholar
• Serra López-Matencio JM, Morell Baladrón A, Castañeda S. Pharmacological interactions of monoclonal antibodies. Med Clin (Barc). 2018;151(4):148–155. English, Spanish.
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030–1040.
   PubMed Web of Science ®Google Scholar
• Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20(1):25.
   PubMed Web of Science ®Google Scholar
• Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814–825.
   PubMed Web of Science ®Google Scholar
• Di Tanna GL, Porter JK, Lipton RB, et al. Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. Health Qual Life Outcomes. 2019;17(1):171.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–e1377.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–e2260.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Almagro D, Achalandabaso A, Rus A, et al. Validation of the Spanish version of the migraine disability assessment questionnaire (MIDAS) in university students with migraine. BMC Neurol. 2020;20(1):67.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. PREEMPT 1 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Doctorovich ED, Martín-Bertuzzi F, Goicochea MT, et al. Consenso sobre el uso de anticuerpos monoclonales en la migraña en Argentina [Argentinean consensus guidelines on the use of monoclonal antibodies in patients with migraine]. Rev Neurol. 2020;70(4):149–158.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Sultan S, et al. GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311–1316.
   PubMed Web of Science ®Google Scholar
• Dalkey NC, Helmer-Hirschberg O. An experimental application of the delphi method to the use of experts. Manage Sci. 1963;9(3):351–515.
   Web of Science ®Google Scholar
• Ayer DW, Skljarevski V, Ford JH, et al. Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2b trial with galcanezumab. Headache. 2018;58(8):1225–1235.
   PubMed Web of Science ®Google Scholar
• Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85(3):283–288.
   PubMed Web of Science ®Google Scholar
• Berger A, Bloudek LM, Varon SF, et al., Adherence with migraine prophylaxis in clinical practice. Pain Pract. 2012;12(7):541–549.
   PubMed Web of Science ®Google Scholar
• Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and prevention study. Headache. 2007;47(3):355–363.
   PubMed Web of Science ®Google Scholar
• Loder EW, Rizzoli P. Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache. 2011;51(8):1336–1345.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• Martelletti P. The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities. BioDrugs. 2017;31(6):483–485.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187–193.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Barbanti P, Aurilia C, Egeo G, et al., Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363–372.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: functional status on headache-free days. Neurology. 2018;91(12):e1152–e1165.
   PubMed Web of Science ®Google Scholar
• De Virgiliis F, Di Giovanni S. Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19. Nat Rev Neurol. 2020;16(11):645–652.
   PubMed Web of Science ®Google Scholar
• Szperka CL, Vander Pluym J, Orr SL, et al. Recommendations on the use of Anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018 Nov;58(10):1658–1669.
   PubMed Web of Science ®Google Scholar
• Assas MB. Anti-migraine agents from an immunological point of view. J Transl Med. 2021 Jan 6;19(1):23. Erratum in: J Transl Med. 2021 Aug 9;19(1):341.
   PubMed Web of Science ®Google Scholar
• Scheffler A, Schenk H, Wurthmann S, et al. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain. 2021;22(1):111.
   PubMed Web of Science ®Google Scholar
• Straube A, Stude P, Gaul C, et al. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain. 2021;22(1):133.
   PubMed Web of Science ®Google Scholar
• Estudio ENE-COVID19: fourth Round National Study of Sero Epidemiology of Infection by SARS-CoV-2 in Spain. Report of December 15th, 2020. [cited 2021 Dec 19]. Available from: [https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/15.12151220163348113.pdf] ( Spanish).
   Google Scholar
• Caronna E, José Gallardo V, Alpuente A, et al. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications. Neurologia (Engl Ed). 2021;36(8):611–617.
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–1774.
   PubMed Web of Science ®Google Scholar
• Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020 Jun 16;21(1):76.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Stauffer VL, Day KA, et al. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019;20(1):75.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al., European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• Pellesi L, Do TP, Ashina H, et al., Dual therapy with Anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60(6):1056–1065.
   PubMed Web of Science ®Google Scholar
• Silvestro M, Tessitore A, Scotto di Clemente F, et al. Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol. 2021;12:656294.
   PubMed Web of Science ®Google Scholar
• Martelletti P. Combination therapy in migraine: asset or issue? Expert Rev Neurother. 2020 Oct;20(10):995–996.
   PubMed Web of Science ®Google Scholar
• De Matteis E, Affaitati G, Frattale I, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021;42(8):3297–3303.
   PubMed Web of Science ®Google Scholar
• Gantenbein AR, Agosti R, Gobbi C, et al., Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment -a real-life cohort study. Cephalalgia. 2021;41(11–12):1181–1186.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2021;42(4-5):326–334.
   Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39(11):1455–1464.
   PubMed Web of Science ®Google Scholar